AlphaRx (OTCBB: ALRX) has begun applying for approval of Indaflex™ in China as a treatment for osteoarthritis, with hopes that the application will be complete by April 2008. If the request is accepted, AlphaRx will conduct a clinical trial of Indaflex™ in China, enrolling 240 patients in a two-arm trial that will treat patients for four weeks. AlphaRx anticipates that the trial will be finished by Q4 of 2008. Indaflex™ is a novel formulation of a standard therapy for osteoarthritis, indomethicin. More details...

Stock Symbol: (OTCBB:ALRX)